Promise's sermorelin page demonstrates why a current review needs more than a search snippet. Indexed material still contains prices, while the live website says visits are paused during a change of prescriber network.
We checked the directly retrieved page and visible website on September 23, 2026. No intake, purchase, or waitlist submission was performed. CoreAge Rx has disclosed commercial placement here; that relationship does not establish a clinical advantage over another provider.
Promise's sermorelin page demonstrates why a current review needs more than a search snippet. Indexed material still contains prices, while the live website.
The stronger source for current access
The live Promise page labels the treatment as coming soon and offers an email notification form. It says the form is not a medical request and does not result in a prescription. That is the current access status observed in this review.
Older search results describe a different version of the page. They are useful evidence that indexed information can lag behind a change, but they do not establish a purchasable offer today. We therefore do not repeat their prices as current amounts.
No reopening date or present checkout price was verified. Promise is listed in an availability watch, not among the active-provider recommendations. A product's continued appearance in search cannot settle whether a new clinical visit is possible.
Separate a future process from present capability
The page retains descriptions of an intended questionnaire, clinician review, prescription when appropriate, and pharmacy fulfillment. These explain a proposed model. The pause notice prevents us from treating them as confirmation of an operating enrollment route today.
A review should not resolve that tension by silently choosing the more attractive passage. It should say which statement governs current access and leave future details unverified until there is a concrete reopened service.
The Pallas review illustrates another limit: a current advertised program can still restrict who it assesses. Availability, eligibility, and the individual prescribing decision are different propositions, each requiring its own evidence.
Legal pages need their own time context
The Promise terms describe platform, clinical, and dispensing responsibilities. Older named relationships on a legal page cannot automatically confirm which organizations will provide care after an announced network transition.
When visits resume, ask for the current clinical network, the clinician responsible for the assessment, and the dispensing pharmacy for any actual prescription. The review should then check that information against the reopened enrollment and applicable terms.
We have not contacted the proposed new network or audited pharmacy assignments. This is not a finding that an older relationship has definitively ended; it is a limit on what can be inferred from the materials available during the pause.
A price requires an available arrangement
Promise's terms say ordering information governs applicable prices and billing conditions. Without a current purchasable offer, an older amount cannot establish the first charge, renewal interval, included services, or cancellation conditions for future care.
If the program returns with different testing or appointment requirements, the old number could describe a materially different purchase. Ask for a complete selected-plan quote rather than combining a cached medication price with assumptions about a new clinical process.
Our published-price guide provides a framework for that check. A price comparison can honestly remain incomplete; filling an unknown field with a historical amount makes it less useful, not more precise.
Medical explanations require another kind of source
Promise describes a proposed hormonal mechanism and links other peptide treatments. Neither a mechanism nor adjacency in a product catalog establishes a clinical benefit for the exact preparation a reader might eventually receive.
A relevant evidence discussion identifies the actual intervention, patient population, measured outcomes, and limits. Our study-population guide and small-study guide explain why those details matter when interpreting historical research.
We have not completed a systematic review of every sermorelin study. This article should not be quoted as proof that no evidence exists or as validation of a particular benefit claim. Its clinical role is to identify questions that need a qualified assessment.
Product status and service status are separate
The FDA's compounding explanation establishes that compounded drugs are not FDA-approved. Reopening a provider's service would not itself alter the regulatory status of the preparation it offers.
Similarly, a pause does not by itself establish a defect in a medicine or a failure of clinical care. The stated reason on the live page is a prescriber-network change. We have not inferred a recall, enforcement action, or other explanation that the reviewed sources do not support.
A careful review can be specific about unavailable access without adding an unsupported negative conclusion. The same standard applies to favorable claims: neither a polished website nor a planned clinician review demonstrates an individual health outcome.
What would justify an update?
A functioning clinical enrollment route, current terms, and a confirmed price would allow a different comparison. Until then, the live pause notice takes precedence over old search content, and the notification form should be described only for its stated purpose.
Read the CoreAge review and CoreAge versus Pallas comparison for other offers evaluated with these source boundaries. The point of the Promise review today is to preserve what is known and mark what is not yet available to verify.
The source notes
Sources & further reading
Provider pages document advertised offers, not independently proven outcomes. Historical references may concern different products or uses. Check the dated discussion in each article for the scope of our research; offers can change.